Form 4: Allogene Therapeutics CEO David Chang Reports Stock and Option Transactions

Allogene Therapeutics CEO David Chang acquired shares and stock options, as well as reporting existing holdings, in a recent SEC filing.

Summary

• David Chang, the President and CEO of Allogene Therapeutics, filed a Form 4 with the SEC detailing changes in his beneficial ownership of the company's stock.
• The filing reports the acquisition of 552,174 shares of common stock at $0 price and 1,952,130 stock options with an exercise price of $1.94.
• The stock options vest over time, with 25% vesting on January 24, 2026, and the remainder vesting in 36 equal monthly installments thereafter.
• The filing also includes details of existing holdings of common stock held directly and indirectly through various trusts.
• The total direct holdings of common stock after the transaction is 5,363,240 shares.
• Indirect holdings include 856,044 shares held in the RTC 2019 Trust, 856,044 shares in the JEC 2019 Trust, and 1,201,108 shares in the Chang 2006 Family Trust.

Sentiment

Score: 6

Explanation: The document is a routine filing of insider transactions. While the acquisition of shares and options could be seen as positive, it's not a major event that would significantly impact sentiment.

Positives

• The acquisition of shares and options by the CEO could be seen as a positive sign of confidence in the company's future.
• The vesting schedule of the options may incentivize long-term performance.

Risks

• The filing itself does not indicate any specific risks, but it is important to monitor insider transactions for potential changes in sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry. It provides transparency into the holdings of key executives.

Comparison to Industry Standards

• Stock option grants and share acquisitions are standard forms of compensation for executives in the biotechnology industry.
• The vesting schedule of the options is typical for incentivizing long-term performance.
• The reporting of holdings through trusts is also a common practice for executives.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the CEO's increased stake in the company.

Key Dates

Keywords

Allogene Therapeutics, David Chang, SEC Form 4, Stock Options, Insider Trading, Beneficial Ownership, Equity Securities